|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2007-1-26
|
|
pubmed:abstractText |
This study evaluated the safety, tolerability, and efficacy of natalizumab, a humanized monoclonal immunoglobulin-G4 antibody to [alpha]4 integrin, in adolescent patients with moderately to severely active Crohn disease (CD).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1536-4801
|
|
pubmed:author |
pubmed-author:DanielsReginaR,
pubmed-author:HeuschkelRobertR,
pubmed-author:HyamsJeffrey SJS,
pubmed-author:International Natalizumab CD305 Trial Group,
pubmed-author:KugathasanSubraS,
pubmed-author:LibonatiMichele AMA,
pubmed-author:MitchellBrentB,
pubmed-author:MittonSallyS,
pubmed-author:ThomasAdrianA,
pubmed-author:WilsonDavid CDC,
pubmed-author:ZankerSusanS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
185-91
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17255829-Adolescent,
pubmed-meshheading:17255829-Antibodies, Monoclonal,
pubmed-meshheading:17255829-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17255829-Child,
pubmed-meshheading:17255829-Crohn Disease,
pubmed-meshheading:17255829-Female,
pubmed-meshheading:17255829-Humans,
pubmed-meshheading:17255829-Immunosuppressive Agents,
pubmed-meshheading:17255829-Integrin alpha4,
pubmed-meshheading:17255829-Male,
pubmed-meshheading:17255829-Quality of Life,
pubmed-meshheading:17255829-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Natalizumab therapy for moderate to severe Crohn disease in adolescents.
|
|
pubmed:affiliation |
Division of Digestive Diseases and Nutrition, Connecticut Children's Medical Center, Hartford, CT 06106, USA. jhyams@ccmckids.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
